Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study

A large international study from the SIOP WT 2001 trial has identified residual absolute volume of blastema as a predictor of clinical outcomes in patients with Wilms tumor, the most common kidney cancer in children. The findings, published in the Journal of Clinical Oncology, suggest that measuring blastema volume after preoperative chemotherapy can help stratify patients by risk and guide treatment intensity. This biomarker could allow clinicians to better identify children who need more aggressive therapy while sparing low-risk patients from unnecessary treatment toxicity. The study represents a meaningful advance in risk stratification for pediatric renal tumors within a well-established cooperative trial framework.